|More than 90% of drugs fail during development, and this is the most significant reason for the high costs of pharmaceutical R&D. A significant advantage of drug repositioning over traditional drug development is that since the repositioned drug has already passed a significant number of toxicity and other tests, its safety is known and the risk of failure for reasons of adverse toxicology are reduced.
Drug repurposing is performed either by using an experimental approach, called 'activity-based drug repositioning', or by making use of a specific computational method.
Compared with activity-based repositioning techniques, in silico methods allow a faster repurposing process at a reduced cost.
Our approach for in silico small molecule and peptide profiling, SAFAN-ISP, is reliable as an experiment but has in-silico times and costs!!!
What is profiling?
If you are looking for drug repositioning opportunities, planning to in-license or out-licence small molecules SAFAN-ISP will help you in evaluating more carefully your investments.
Last update: 9/7/2018